We are delighted to welcome Dr. Uwe Gottschalk to Biovian’s Board of Directors. “At Keensight, we are very pleased to welcome Uwe to the Board of Biovian” said Dr. Pierre Remy, Chairman of the Board. …
Biovian is delighted to announce that Allison Allen has been appointed the first US-based Head of Global Business Development. “We are very pleased that Allison Allen will assume the role Business Development Manager at Biovian” …
Biovian is looking forward to participating in the BIO International Convention on June 13th-16th in San Diego. #BIO2022 is back in person. Biovian representatives, CBO Magnus Gustafsson and Head of Business Development Eero Mustalahti are …
Viral contaminations are rare events in biopharmaceutical manufacturing, but regulatory agencies expect all biologics to undergo viral clearance testing to mitigate the risk of contamination [1, 2]. Therapies based on viral vectors have a small …
ANLBIO, a biotechnology company developing gene therapies for neurodegenerative diseases, has selected Biovian Oy as a CDMO partner. The agreement covers process development for ANLBIO’s proprietary gene therapy vector, ANL-101, followed by 200 L scale …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
New Horizons 2021 event took place on December 9th in Stockholm. Dr. Magnus Gustafsson from Biovian gave a talk about “Gene therapy today and tomorrow.” New Horizons is an international educational forum that focuses on …
Biovian and Lokon Pharma are featured in Biopharma Dealmakers September issue. The article “Manufacturing the next generation of cancer immunotherapeutics”, describes the history and currents state of Lokon Pharma’s proprietary LOAd technology. This immunostimulatory gene …
Here we present some basic concepts of Viral Vectors used in gene therapy applications with special focus on AAV and Adenovirus vectors. Please proceed to this page if you are looking for information about our …
The leading regional newspaper of of the Southwest Finland interviewed Knut Ringbom, the CEO of Biovian about the COVID-19 vaccine manufacturing possibilities. “Pandemic vaccine manufacturing is a hot topic. We have been contacted by European …
